INTRODUCTION
Screening with sputum cytology and chest x-ray had no impact on mortality from lung cancer. This was the surprising result of trials of the 1970s and early 1980s sponsored by the National Cancer Institute (NCI). The trials were performed at Johns Hopkins Medical Center, the Memorial Sloan-Kettering Medical Center, and the Mayo Clinic (1) (2) (3) (4) (5) (6) . The result has generated significant controversy and discussion ofthe implications ofthe use ofchest x-ray and sputum cytology in clinical practice in the United States.
NCI-SPONSORED TRIALS
The two NCI-sponsored trials performed at Johns Hopkins and Memorial Sloan-Kettering studied the impact of sputum cytology every 4 months in addition to an annual chest x-ray and compared it with a control group that had only the annual chest x-ray (2-4). The study was designed to determine the effect of sputum cytology on lung cancer.
The results at these two centers showed no difference in mortality, strong evidence that sputum is of no additional value to the annual chest x-ray. There was a slight trend for decreased mortality in the squamous cell carcinoma group, but the design of the study was not intended to specifically assess the impact of screening on any particular cell type. Rather, the studies were designed to determine the overall impact of sputum cytology on mortality from lung cancer.
The design of the Mayo Clinic study was different (5) .
This study compared the impact of sputum cytology and chest x-ray every 4 months compared with a standard recommendation of a yearly sputum test and a chest x-ray. More cancers were identified in the group screened with sputum cytology and chest x-ray every 4 months. More cancers were of early stage and, therefore, more were resected in the screened group. However, there was no difference in the mortality from lung cancer between the two groups (7, 8) .
From November 1971 through July 1983, a total of 366 incidence cases of lung cancer were identified among the patients enrolled at Mayo. In the group that received every 4-month chest x-ray and sputum cytology, there were 206 patients identified with lung cancer for an incidence rate of5.5/1,000 years. In the control group, the group advised to have an annual chest x-ray and sputum cytology, there were 160 patients with lung cancer for an incidence rate of 4.3/1,000 years.
Of There are at least four important observations from this information. First, only 9% of patients in the screened group had cancer detected by sputum cytology alone. Second, more patients in the screened group underwent resection because of the sputum cytology and the screening chest x-ray. Third, a smaller percentage of patients in the screened group presented with symptoms at the time of detection. Finally, the results in both the study and control groups show that less than 13% of patients have resectable cancers when they present with symptoms (7, 8) .
In some aspects, screening for lung cancer appears to have been a success. In the study group, there were more lung cancers detected, they were more localized and therefore, more likely to be resected for potential cure. Theoretically, there should, have been a reduction in the mortality from lung cancer in the study group compared to the control group. The surprising finding was that the death rates in the Mayo study were the same. In the four monthly screened group, 122 patients died of lung cancer for a death rate of 3.2/1,000 years. In the control group, 115 patients were identified as dying from lung cancer for a death rate of 3.0/1,000 years. The death rates in both groups related to all causes of death were similar at 24.9/1,000 years and 24.8/1,000 years in the study and the control groups, respectively.
This unexpected result has intrigued physicians for the past 15 years. Possible explanations for the failure of screening to reduce mortality include: the size of the study groups, the statistical power of the study, the distribution of the cell types, overdiagnosis of clinically unimportant cancers, statistical chance, and ineffective therapy.
There were a number of initial assumptions in the original study that proved erroneous. Cytologic examination of the sputum was expected to detect 30 to 33% of all lung cancers, yet only 9% of the patients had cancer detected by sputum cytology alone. A lower percentage of patients had squamous cell carcinoma while a higher percentage of patients had adenocarcinoma and small cell carcinoma than anticipated. It was expected that mortality from lung cancer would not be affected by an annual chest x-ray, yet it appeared that the annual chest x-ray played the biggest role in the detection of these cancers. It was expected that deaths from lung cancer would be easy to determine and identify, but this did not prove to be the case, particularly in the control group. And finally, it was anticipated that the number of lung cancers in the control group would equal the number in the 4-monthly screened group.
The cell type has dramatic prognostic implications.
Squamous cell carcinoma and adenocarcinoma, even when roentgenographically occult, behave as different cancers (9 (11) . In adenocarcinoma, positive sputum is obtained in no more than 25% of the patients. Adenocarcinoma is very rarely roentgenographically occult. When sputum cytology is positive more than 70% ofthe patients will have nodal disease. The 5-year survival of patients with adenocarcinoma when the sputum cytology is positive is 0%. Small cell carcinoma, ofcourse, is rapidly progressive and when sputum cytology is positive, it is invariably at an advanced stage. Therefore, the distribution of cell type in a patient population will have a great impact on the ability of sputum cytology to reduce mortality. The possibility of overdiagnosis of lung cancer when it was not clinically significant, was a concern in the Mayo study. However, other studies indicate that lung cancer is usually virulent. In an autopsy series published in 1968 of 3,286 patients, 26 unsuspected lung cancers were found (12) . Of these, nodal involvement was found in 57%. Most of the cancers contributed to the patient's death although it was not suspected at the time of death. The conclusion of these authors was that lung cancer was not likely to remain clinically latent for long (12, 13 Mayo lung project had a 90% probability to detect a mortality reduction of 50%. However, the study had only a 40% probability to detect a mortality reduction ofless than 20% between the two groups.
CONCLUSIONS
With all this information, the only conclusions that can be drawn from the NCI-sponsored studies are: 1) there are insufficient data to conclude that chest x-rays are of no value in lung cancer screening since all patients in all groups in all three centers received chest x-rays, and 2) there are no definite data that sputum cytology testing adds to the chest x-ray in the screening and treatment for lung cancer. As a result, the NCI is funding a new series of trials in the United States. For these trials, patients (men and women) between the ages of 60 and 74 will be enrolled. The sample size will be 74,000 patients in each group for a total of 148,000 patients. This study is to have a 90% power to detect a reduction in mortality of 10%. These trials are just getting underway; unfortunately we will have to wait many years before the results are known. It is certain that we will learn much about lung cancer during these trials, and we hope it will benefit our patients.
